$16.80
0.96% today
Nasdaq, Aug 25, 05:50 pm CET
ISIN
US07373V1052
Symbol
BEAM

Beam Therapeutics Inc Stock price

$16.64
-4.90 22.75% 1M
-14.15 45.96% 6M
-8.16 32.90% YTD
-7.88 32.14% 1Y
-34.77 67.63% 3Y
-9.02 35.15% 5Y
-2.11 11.25% 10Y
-2.11 11.25% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.63 3.94%
ISIN
US07373V1052
Symbol
BEAM
Industry

Key metrics

Basic
Market capitalization
$1.7b
Enterprise Value
$533.0m
Net debt
positive
Cash
$1.2b
Shares outstanding
100.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
27.9 | 36.6
EV/Sales
8.8 | 11.6
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
66.5%
Return on Equity
-51.4%
ROCE
-36.6%
ROIC
-370.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$60.3m | $46.0m
EBITDA
$-424.0m | $-473.4m
EBIT
$-446.0m | $-476.7m
Net Income
$-398.6m | $-451.3m
Free Cash Flow
$-355.6m
Growth (TTM | estimate)
Revenue
-82.9% | -27.6%
EBITDA
-160.2% | -20.3%
EBIT
-141.8% | -14.7%
Net Income
-178.7% | -19.8%
Free Cash Flow
-131.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-703.5% | -1,029.2%
EBIT
-739.9%
Net
-661.3% | -981.1%
Free Cash Flow
-590.0%
More
EPS
$-3.9
FCF per Share
$-3.5
Short interest
27.4%
Employees
483
Rev per Employee
$130.0k
Show more

Is Beam Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Beam Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Beam Therapeutics Inc forecast:

19x Buy
83%
4x Hold
17%

Analyst Opinions

23 Analysts have issued a Beam Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Beam Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
60 60
83% 83%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 110 110
12% 12%
182%
- Research and Development Expense 396 396
4% 4%
658%
-424 -424
160% 160%
-703%
- Depreciation and Amortization 22 22
2% 2%
36%
EBIT (Operating Income) EBIT -446 -446
142% 142%
-740%
Net Profit -399 -399
179% 179%
-661%

In millions USD.

Don't miss a Thing! We will send you all news about Beam Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Beam Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 5 hours ago
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m.
Neutral
GlobeNewsWire
11 days ago
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for ...
Neutral
GlobeNewsWire
20 days ago
With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile
More Beam Therapeutics Inc News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Head office United States
CEO John Evans
Employees 483
Founded 2017
Website beamtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today